Osteoprotegerin and myocardial fibrosis in patients with aortic stenosis

Brodie L. Loudon, Eleana Ntatsaki, Simon Newsome, Brian Halliday, Amrit Lota, Aamir Ali, Tamir Malley, Subothini Selvendran, Nikhil Aggarwal, Willis Lam, Jackie Donovan, Dominque Auger, Claire E. Raphael, Paul D. Flynn, Dudley J. Pennell, Vassilios S. Vassiliou, Sanjay K. Prasad

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
12 Downloads (Pure)


Left ventricular myocardial fibrosis in patients with aortic stenosis (AS) confers worse prognosis. Plasma osteoprotegerin (OPG), a cytokine from the TNF receptor family, correlates with the degree of valve calcification in AS, reflecting the activity of the tissue RANKL/RANK/OPG (receptor activator of nuclear factor κΒ ligand/RANK/osteoprotegerin) axis, and is associated with poorer outcomes in AS. Its association with myocardial fibrosis is unknown. We hypothesised that OPG levels would reflect the extent of myocardial fibrosis in AS. We included 110 consecutive patients with AS who had undergone late-gadolinium contrast enhanced cardiovascular magnetic resonance (LGE-CMR). Patients were characterised according to pattern of fibrosis (no fibrosis, midwall fibrosis, or chronic myocardial infarction fibrosis). Serum OPG was measured with ELISA and compared between groups defined by valve stenosis severity. Some 36 patients had no fibrosis, 38 had midwall fibrosis, and 36 had chronic infarction. Patients with midwall fibrosis did not have higher levels of OPG compared to those without fibrosis (6.78 vs. 5.25 pmol/L, p = 0.12). There was no difference between those with midwall or chronic myocardial infarction fibrosis (6.78 vs. 6.97 pmol/L, p = 0.27). However, OPG levels in patients with chronic myocardial infarction fibrosis were significantly higher than those without fibrosis (p = 0.005).

Original languageEnglish
Article number14550
JournalScientific Reports
Publication statusPublished - 28 Sep 2018

Cite this